Peloruside A, an antimitotic agent, specifically decreases tumor necrosis factor-α production by lipopolysaccharide-stimulated murine macrophages

Experimental Biology and Medicine

Volumn 232, Issue 5, 2007, Pages 607-613

  Crume, Kevin P ^a   Miller, John H ^a   La Flamme, Anne C ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

Inflammation; Macrophage; Microtubule stabilizing agent; Peloruside; Taxol

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTIMITOTIC AGENT; CONCANAVALIN A; INTERLEUKIN 12P40; LIPOPOLYSACCHARIDE; NITRIC OXIDE; PACLITAXEL; PELORUSIDE A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SECRETION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DOWN REGULATION; IMMUNOMODULATION; MACROPHAGE; MALE; MICROTUBULE; MITOSIS INHIBITION; MOUSE; NONHUMAN; SPLEEN CELL;

ANIMALS; ANTIMITOTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BONE MARROW CELLS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERLEUKIN-12 SUBUNIT P40; LACTONES; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; PACLITAXEL; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 34247617334     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. West LM, Northcote PT, Battershill CN. Peloruside A: a potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem 65:445-449, 2000.
2. Hood KA, West LM, Rouwe B, Northcote PT, Berridge MV, Wakefield SJ, Miller JH. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res 62:3356-3360, 2002.
3. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325-2327, 1971.
4. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9(Suppl 2):3-8, 2004.
5. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22:9075-9086, 2003.
6. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 48:4093-4100, 1988.
7. Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol 94:688-696, 1982.
8. Donaldson KL, Goolsby GL, Wahl AF. Cytotoxicity of the anticancer agents cisplatin and Taxol during cell proliferation and the cell cycle. Int J Cancer 57:847-855, 1994.
9. Fuchs DA, Johnson RK. Cytologic evidence that Taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 62:1219-1222, 1978.
10. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667, 1979.
11. Gaitanos TN, Buey RM, Díaz JF, Northcote PT, Teesdale-Spittle P, Andreu JM, Miller JH. Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res 64:5063-5067, 2004.
12. Hood KA, Bäckström BT, West LM, Northcote PT, Berridge MV, Miller JH. The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C. Anticancer Drug Des 16:155-166, 2001.
13. Ding AH, Porteu F, Sanchez E, Nathan CF. Shared actions of endotoxin and Taxol on TNF receptors and TNF release. Science 248:370-372, 1990.
14. Fitzpatrick FA, Wheeler R. The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol 3:1699-1714, 2003.
15. Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother 49:181-185, 2000.
16. Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 31:2448-2457, 2001.
17. Manthey CL, Perera PY, Salkowski CA, Vogel SN. Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol 152:825-831, 1994.
18. Celada A, Gray PW, Rinderknecht E, Schreiber RD. Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med 160:55-74, 1984.
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63, 1983.
20. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119:203-210, 1989.
21. Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11:127-152, 2005.
22. 15N-nitrate in biological fluids. Anal Biochem 126:131-138, 1982.
23. Brunet LR, Finkelman FD, Cheever AW, Kopf MA, Pearce EJ. IL-4 protects against TNF-alpha-mediated cachexia and death during acute schistosomiasis. J Immunol 159:777-785, 1997.
24. Brown DL, Little JE, Chaly N, Schweitzer I, Paulin-Levasseur M. Effects of Taxol on microtubule organization in mouse splenic lymphocytes and on response to mitogenic stimulation. Eur J Cell Biol 37:130-139, 1985.
25. Jimenez-Barbero J, Canales A, Northcote PT, Buey RM, Andreu JM, Díaz JF. NMR determination of the bioactive conformation of peloruside A bound to microtubules. J Am Chem Soc 128:8757-8765, 2006.
26. Pineda O, Farras J, Maccari L, Manetti F, Botta M, Vilarrasa J. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with Taxol and colchicine. Bioorg Med Chem Lett 14:4825-4829, 2004.
27. Kirikae T, Ojima I, Kirikae F, Ma Z, Kuduk SD, Slater JC, Takeuchi CS, Bounaud PY, Nakano M. Structural requirements of taxoids for nitric oxide and tumor necrosis factor production by murine macrophages. Biochem Biophys Res Commun 227:227-235, 1996.
28. Manthey CL, Qureshi N, Stutz PL, Vogel SN. Lipopolysaccharide antagonists block Taxol-induced signaling in murine macrophages. J Exp Med 178:695-702, 1993.
29. Muhlradt PF, Sasse F. Epothilone B stabilizes microtubuli of macrophages like Taxol without showing Taxol-like endotoxin activity. Cancer Res 57:3344-3346, 1997.
30. Bogdan C, Ding A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 52:119-121, 1992.
31. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A 100:5336-5341, 2003.
32. Miller JH, Rouwe B, Gaitanos TN, Hood KA, Crume KP, Bäckström BT, La Flamme AC, Berridge MV, Northcote PT. Peloruside A enhances apoptosis in H-ras-transformed cells and is cytotoxic to proliferating T cells. Apoptosis 9:785-796, 2004.
33. Lee M, Yea SS, Jeon YJ. Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipopolysaccharide stimulation. Int J Immunopharmacol 22:615-621, 2000.
34. Jordan M, Toso R, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci U S A 90:9552-9556, 1993.
35. Vila-Del Sol V, Diaz-Munoz MD, Fresno M. Requirement of tumor necrosis factor alpha and nuclear factor-kappaB in the induction by IFN-gamma of inducible nitric oxide synthase in macrophages. J Leukoc Biol 81:272-283, 2007.
36. Kim YM, Paik SG. Induction of expression of inducible nitric oxide synthase by Taxol in murine macrophage cells. Biochem Biophys Res Commun 326:410-416, 2005.
37. Miljkovic D, Cvetkovic I, Sajic M, Vuckovic O, Harhaji L, Markovic M, Trajkovic V. 5-Aza-2′-deoxycytidine and paclitaxel inhibit inducible nitric oxide synthase activation in fibrosarcoma cells. Eur J Pharmacol 485:81-88, 2004.
38. Rao P, Falk L, Dougherty S, Sawada T, Pluznik D. Colchicine downregulates lipopolysaccharide-induced granulocyte-macrophage colony-stimulating factor production in murine macrophages. J Immunol 159:3531-3539, 1997.
39. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87:21-27, 2002.
40. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364-371, 2002.
41. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440, 1996